We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.

In a recent study posted to the bioRxiv* preprint server, researchers compared the severity levels of disease caused by different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in the rhesus macaque model.

The whole-genome sequencing (WGS) of SARS-CoV-2 genomes led to early detection of its VOCs, which are those variants that display increased transmissibility and disease severity. So far, WGS has helped researchers identify five SARS-CoV-2 VOCs, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529). Animal models allow comparing their infection dynamics circumventing population-wide confounding factors, such as previous SARS-CoV-2 infections and vaccine coverage, which makes it challenging to identify the evolutionary significance of each VOC in the human population.

In the present study, researchers utilized the rhesus macaque model to examine differences in pathogenicity between SARS-CoV-2 Delta, Omicron BA.1, and Omicron BA.2 VOCs. They used baby hamster kidney cells (BHKs) expressing the human or rhesus angiotensin-converting enzyme 2 (ACE2). Likewise, they used pseudotyped vesicular stomatitis virus (VSV) expressing the S protein of the Delta, Omicron BA.1, and Omicron BA.2 VOCs to examine the entry profile of the respective VOCs.

The team made three groups of six rhesus macaques, which were intranasally and intratracheally inoculated with 2 × 106 median tissue culture infective dose (TCID50) of Delta, or Omicron BA.1 and BA.2 VOCs. The researchers collected nasal swabs from infected animals at zero-, two-, four-, and six-days post inoculation (dpi). They detected the presence of viral genomic ribonucleic acid (gRNA) and subgenomic RNA (sgRNA) in the bronchial cytology brush (BCB and bronchoalveolar lavage (BAL) samples of the test animals. Further, the team developed an area under the curve for each animal - a measure of the total amount of viral gRNA and sgRNA shed between two- and six dpi.

They euthanized the test animals at six dpi to collect tissues from the upper and lower respiratory tract and intestinal tract. The team analyzed radiographs of all animals for the presence of pulmonary infiltrates. Lastly, the researchers analyzed nasosorption, serum, and BAL samples for the presence of nine different cytokines.

Most test animals across all three study groups had days of reduced appetite throughout the study. However, the researchers observed respiratory signs in four Delta-infected animals, one Omicron BA.2 infected animal, and none with Omicron BA.1 infection. Compared to Delta, Omicron showed reduced entry into the BHK cell line. Moreover, in nasal swabs, Omicron sub-variants resembled D614G, Alpha, and Beta, whereas the viral load in animals inoculated with the Delta VOC was higher. In BCB samples and the lung tissues, viral load was highest for the Delta VOC only. The presence of viral RNA was also limited in oropharyngeal and rectal swabs compared to nasal swabs and the blood samples too had no viral RNA on any exam day.

Similar to nasal swab samples, BAL and BCB samples had the highest viral load on two dpi, which declined between four and six dpi. While the authors detected less viral RNA in BCB samples of animals inoculated with Omicron BA.1 or BA.2 compared to Delta, there were no significant differences between groups in the amount of viral RNA detected in BAL samples.

Although the systemic response was comparable, cytokines and chemokines were upregulated to higher levels in Delta-inoculated animals than in Omicron BA.1 or BA.2-inoculated animals in the upper respiratory tract. The nasosorption samples obtained from animals challenged with Delta had elevated IL-1 receptor antagonist (IL1- RA), interleukin-6 (IL-6), IL-15, and tumor necrosis factor-α (TNF-α) on all days, with only a few changes in cytokine and chemokine levels in BAL samples. Conversely, serum samples showed similar responses across all groups up to two dpi, with slight divergences by six dpi.

The viral RNA was mostly limited to the respiratory tract in Omicron-inoculated animals, whereas viral RNA in Delta-inoculated animals was found even in extra-respiratory tissues.

Overall, the study data suggested that Omicron replicated less than the Delta VOC in rhesus macaques, resulting in reduced clinical disease, further supporting the notion that Omicron infection results in less severe disease even in the absence of pre-existing immunity. Further, the study data showing a reduction in viral load, disease, and pathology following Omicron BA.1 and BA.2 infection reflects observations in the human population.

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Posted in: Medical Science News | Medical Research News | Disease/Infection News

Tags: ACE2, Angiotensin, Angiotensin-Converting Enzyme 2, Baby, Blood, Cell, Cell Line, Chemokine, Chemokines, Coronavirus, Coronavirus Disease COVID-19, Cytokine, Cytokines, Cytology, Enzyme, Genome, Genomic, immunity, Interleukin, Interleukin-6, Kidney, Necrosis, Omicron, Pathology, Protein, Receptor, Respiratory, Ribonucleic Acid, RNA, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Stomatitis, Syndrome, Tissue Culture, Tumor, Tumor Necrosis Factor, Vaccine, Virus

Neha is a digital marketing professional based in Gurugram, India. She has a Master’s degree from the University of Rajasthan with a specialization in Biotechnology in 2008. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. She also holds a certification in C++ programming.

Please use one of the following formats to cite this article in your essay, paper or report:

Mathur, Neha. (2022, August 04). Disease progression in the rhesus macaque model upon inoculation with the Delta, Omicron BA.1, and Omicron BA.2 variants. News-Medical. Retrieved on August 08, 2022 from https://www.news-medical.net/news/20220804/Disease-progression-in-the-rhesus-macaque-model-upon-inoculation-with-the-Delta-Omicron-BA1-and-Omicron-BA2-variants.aspx.

Mathur, Neha. "Disease progression in the rhesus macaque model upon inoculation with the Delta, Omicron BA.1, and Omicron BA.2 variants". News-Medical. 08 August 2022. <https://www.news-medical.net/news/20220804/Disease-progression-in-the-rhesus-macaque-model-upon-inoculation-with-the-Delta-Omicron-BA1-and-Omicron-BA2-variants.aspx>.

Mathur, Neha. "Disease progression in the rhesus macaque model upon inoculation with the Delta, Omicron BA.1, and Omicron BA.2 variants". News-Medical. https://www.news-medical.net/news/20220804/Disease-progression-in-the-rhesus-macaque-model-upon-inoculation-with-the-Delta-Omicron-BA1-and-Omicron-BA2-variants.aspx. (accessed August 08, 2022).

Mathur, Neha. 2022. Disease progression in the rhesus macaque model upon inoculation with the Delta, Omicron BA.1, and Omicron BA.2 variants. News-Medical, viewed 08 August 2022, https://www.news-medical.net/news/20220804/Disease-progression-in-the-rhesus-macaque-model-upon-inoculation-with-the-Delta-Omicron-BA1-and-Omicron-BA2-variants.aspx.

In this interview, we speak to Charles Wells from Gates MRI about their current research into tuberculosis (TB) as well as the recent updated guidelines for TB care.

In this interview, we speak to Dr. Jordan Green about his latest research partnership with Modality.AI that investigated whether an app could be used to effectively diagnose speech decline due to ALS.

In this interview, we speak to Tom Kostrzewski, VP of Science and Technology at CN Bio, about their organ-on-a-chip product and the future of drug discovery.

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

This site complies with the HONcode standard for trustworthy health information: verify here.

News-Medical.net - An AZoNetwork Site

Owned and operated by AZoNetwork, © 2000-2022